UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-QSB
(Mark One)
(X) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended: September 30, 2003
( ) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transition period from __________ to __________
Commission File Number: 33-63474
CALLISTO PHARMACEUTICALS, INC.
------------------------------
(Exact name of Registrant as specified in its charter)
Delaware 13-3894575
-------- ----------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
420 Lexington Avenue, Suite 2500, New York, New York 10170
---------------------------------------------------- -----
(Address of principal executive offices) (Zip Code)
(212) 297-0010
--------------
(Registrant's telephone number)
(Former Name, Former Address and Former Fiscal Year,
if changed since last report)
APPLICABLE ONLY TO CORPORATE ISSUERS:
State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practicable date:
Class Outstanding at November 13, 2003
----- --------------------------------
Common Stock, par value $0.0001 23,404,821 shares
Transitional Small Business Disclosure Format (check one): Yes No |X|
CALLISTO PHARMACEUTICALS, INC.
FORM 10-QSB
CONTENTS
PART I -- FINANCIAL INFORMATION Page
-----------
Item 1. Condensed Consolidated Financial Statements
Unaudited Condensed Consolidated Balance Sheet as of September 30, 1
2003
Unaudited Condensed Consolidated Statements of Operations for the 2
Three and Nine Months Ended September 30, 2003 and 2002 and the
period June 5, 1996 (Inception) to September 30, 2003
Unaudited Condensed Consolidated Statements of Cash 3
Flows for the Nine Months Ended September 30, 2003 and
2002 and for the period September 5, 1996 (Inception) to
September 30, 2003
Notes to Unaudited Condensed Consolidated Financial Statements 4
Item 2. Management's Discussion and Analysis of Financial Condition and 11
Results of Operations
Item 3. Controls and Procedures 16
PART II -- OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K 17
Signatures 18
i
INTRODUCTORY NOTE
This Report on Form 10-QSB for Callisto Pharmaceuticals, Inc. (the "Company")
may contain forward-looking statements. You can identify these statements by
forward-looking words such as "may," "will," "expect," "intend," "anticipate,"
believe," "estimate" and "continue" or similar words. Forward-looking statements
include information concerning possible or assumed future business success or
financial results. You should read statements that contain these words carefully
because they discuss future expectations and plans, which contain projections of
future results of operations or financial condition or state other
forward-looking information. We believe that it is important to communicate
future expectations to investors. However, there may be events in the future
that we are not able to accurately predict or control. Accordingly, we do not
undertake any obligation to update any forward-looking statements for any
reason, even if new information becomes available or other events occur in the
future.
The forward-looking statements included herein are based on current expectations
that involve a number of risks and uncertainties set forth under "Risk Factors"
in our Report on Form 8-K and other periodic reports filed with the SEC.
Accordingly, to the extent that this Report contains forward-looking statements
regarding the acquisitions, financial condition, operating results, business
prospects or any other aspect of the Company, please be advised that the
Company's actual financial condition, operating results and business performance
may differ materially from that projected or estimated by the Company in
forward-looking statements.
PART I - FINANCIAL INFORMATION
Item 1. Condensed Consolidated Financial Statements
CALLISTO PHARMACEUTICALS, INC.
(A Development Stage Company)
CONDENSED CONSOLIDATED BALANCE SHEET as of September 30, 2003
(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents $ 703,903
Prepaid insurance ($107,387) and other current assets 112,484
------------
816,387
------------
Fixed assets, net of accumulated
depreciation of $26,388 59,537
------------
Other assets:
Rent deposit 47,246
------------
47,246
------------
$ 923,170
============
LIABILITIES AND SHAREHOLDERS' DEFICIT
Accounts payable, accruals and other current liabilities $ 1,050,952
------------
Shareholders' deficit:
Common stock $.0001 par value, 60,000,000 authorized
shares and issued and outstanding
23,204,851 2,319
Additional paid-in-capital 27,505,551
Unamortized deferred stock based compensation (6,239,033)
Accumulated deficit during the development stage (21,396,619)
------------
(127,782)
------------
$ 923,170
============
The accompanying notes are an integral part of these condensed consolidated
financial statements
CALLISTO PHAMACEUTICALS, INC.
(A Development Stage Company)
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(Unaudited)
Three Months Ended Nine Months Ended June 5, 1996
---------------------------- --------------------------- (Inception) to
September 30, September 30, September 30,
2003 2002 2003 2002 2003
------------ ------------ ------------ ------------ ------------
Revenues $ - $ - $ - $ - $ -
------------ ------------ ------------ ------------ ------------
Costs and expenses:
Research and development 576,266 141,717 885,252 440,244 4,414,743
General and administrative 340,912 187,001 831,474 805,832 5,228,911
Purchased in-process R&D (19,091) - 6,814,363 - 6,814,363
Stock based compensation 468,437 81,027 3,774,987 248,981 4,938,602
------------ ------------ ------------ ------------ ------------
Net loss $ (1,366,524) $ (409,745) $(12,306,076) $ (1,495,057) $(21,396,619)
============= ============ ============ ============ ============
Weighted average shares outstanding:
basic and diluted 23,209,139 17,318,994 20,621,950 17,318,994 -
Net loss per common share:
basic and diluted ($0.06) ($0.02) ($0.60) ($0.09) -
The accompanying notes are an integral part of these condensed consolidated
financial statements
CALLISTO PHAMACEUTICALS, INC.
(A Development Stage Company)
CONDENSED CONSOLIDATED STATEMENT OF CASHFLOWS
(Unaudited)
Nine Months Nine Months June 5, 1996
Months Ended Months Ended (Inception) to
September 30, 2003 September 30, 2002 September 30, 2003
------------------ ------------------ ------------------
Cash flows from operating activities:
Net loss ($12,306,076) ($ 1,495,057) ($21,396,619)
Adjustments to reconcile net loss to net cash
used in operating activities:
Purchased in process research and
development 6,814,363 - 6,814,363
Stock based compensation 3,774,987 248,981 4,938,602
Depreciation and amortization 14,261 5,084 26,388
Unrealized loss on investment - - 30,986
Common and preferred stock issued for
services - - 91,667
Cancellation in note receivable - - 91,770
Increase in note receivable - -
(91,770)
Changes in operating assets and liabilities:
Increase in prepaid and other current
assets (84,028) 8,204 (112,484)
Increase in accounts payable, accruals
and other liabilities 369,930 42,941 1,039,008
------------ ------------ ------------
Total adjustments
10,889,513 305,210 12,828,530
Net cash used in operating activities (1,416,563) (1,189,847) (8,568,089)
Cash flows from investing activities:
Acquisition of furniture & equipment (55,750) (22,029) (85,925)
Rent deposit (47,246) - (47,246)
Proceeds (loss) on sale of marketable
securities - - (30,986)
------------ ------------ ------------
Net cash (used in) provided by investing
activities (102,996) (22,029) (164,157)
Cash flows from financing activities:
Issuance of common and preferred stock
(net of repurchases) - - 9,436,149
------------ ------------ ------------
Net cash (used in) provided by financing
activities - - 9,436,149
Net (decrease) increase in cash and cash
equivalents (1,519,559) (1,211,876) 703,903
Cash and cash equivalent at beginning of period 2,223,462 3,627,479 -
------------ ------------ ------------
Cash and cash equivalent at end of period $ 703,903 $ 2,415,603 $ 703,903
Supplementary disclosures of cash flows
information:
Cash paid for taxes $ 23,091 $ 13,487 $ 59,569
The accompanying notes are an integral part of these condensed
consolidated financial statements
CALLISTO PHAMACEUTICALS, INC.
(A Development Stage Company)
NOTES TO SEPTEMBER 30, 2003 CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (UNAUDITED)
1. Basis of presentation:
The accompanying unaudited condensed consolidated financial statements of
Callisto Pharmaceuticals, Inc., and its wholly owned subsidiary Synergy
Pharmaceuticals Inc. ("Synergy") acquired April 30, 2003 (collectively
"Callisto" a development stage company), have been prepared in accordance with
accounting principles generally accepted in the United States ("GAAP") for
interim financial information and the rules of the Securities and Exchange
Commission (the "SEC") for quarterly reports on Form 10-QSB and do not include
all of the information and footnote disclosures required by GAAP for complete
financial statements. Certain prior year expenses in our Condensed Consolidated
Statement of Operations have been reclassified to conform to our current year
results. These statements should be read in conjunction with the Callisto's
audited financial statements and notes thereto for the year ended December 31,
2002, included in Form 8K filed with the SEC on May 15, 2003.
During the quarter ended September 30, 2003 Callisto made certain adjustments to
correct its financial statements for the three and six months ended June 30,
2003, filed on Form 10-QSB. The effect of these adjustments has been included in
the balances as of and for the nine months ended September 30, 2003. Callisto
intends to file an amended Form 10-QSB for the quarter ended June 30, 2003
shortly. The following is a summary of the impact of these adjustments:
Net loss for the six months ended June 30, 2003 - as reported ($10,083,910)
Net loss for the six months ended June 30, 2003 - restated ($10,939,552)
Accumulated Deficit June 30, 2003 - as reported ($19,695,989)
Accumulated Deficit June 30, 2003 - restated ($20,030,095)
In the opinion of management, the accompanying unaudited condensed consolidated
financial statements include all adjustments, primarily consisting of normal
adjustments, necessary for the fair presentation of the balance sheet and
results of operations for the interim periods. The results of operations for the
three and nine months ended September 30, 2003 are not necessarily indicative of
the results of operations to be expected for the full year ending December 31,
2003.
The accompanying unaudited condensed consolidated financial statements have been
prepared assuming that Callisto will continue as a going concern. Management
believes that current resources will be sufficient to support its planned
operations through the fourth quarter 2003. Callisto does not have commercial
biopharmaceutical products, and does not expect to have such for several years,
if at all. In addition, the merger of Callisto with Synergy in April 2003 has
required additional cash to integrate the combined companies. Callisto believes
that it will need additional funds to complete the development of its biomedical
products and pursue FDA approval. These circumstances raise substantial doubt
about Callisto's ability to continue as a going concern beyond December 31,
2003. Management's plans with regard to these matters include continued
development of its products as well as seeking additional research support funds
and financial arrangements. We are also in the process of raising additional
capital through a private placement of common stock which began in July 2003.
Although management continues to pursue these plans, there is no assurance that
Callisto will be successful in obtaining sufficient financing on terms
acceptable to Callisto. In the event that Callisto is unable to raise additional
funds, planned operations will need to be scaled back or discontinued. The
financial statements do not include any adjustments that might result from the
outcome of these uncertainties. In November 2003, Callisto closed on a
sufficient amount of funds in a private placement of common stock such that it
no longer had a working capital deficiency.
2. Significant Accounting Policies
Business Combinations
Callisto accounts for business combinations in accordance with the provisions of
Statement of Financial Accounting Standards No. 141 "Business Combinations"
("SFAS 141"). SFAS 141 requires business combinations completed after June 30,
2001 to be accounted for using the purchase method of accounting. It also
specifies the types of acquired intangible assets required to be recognized and
reported separately from goodwill.
Long-lived assets
Callisto accounts for long-lived assets in accordance with the provisions of
Statement of Financial Accounting Standards No. 144, "Accounting for the
Impairment or Disposal of Long-Lived Assets" ("SFAS 144"). SFAS 144 requires
that long-lived assets be reviewed for impairment whenever events or changes in
circumstances indicate that the carrying amount of the asset may not be
recoverable. Callisto compares the carrying amount of the asset to the estimated
undiscounted future cash flows expected to result from the use of the asset. If
the carrying amount of the asset exceeds estimated expected undiscounted future
cash flows, Callisto records an impairment charge for the difference between the
carrying amount of the asset and its fair value. Changes in events or
circumstances impacting long-lived assets include, but are not limited to,
cancellations or terminations of research contracts or pending government
research grants.
Income taxes
Income taxes are accounted for under the asset and liability method prescribed
by Statement of Financial Accounting Standards No. 109, "Accounting for Income
Taxes." Deferred income taxes are recorded for temporary differences between
financial statement carrying amounts and the tax basis of assets and
liabilities. Deferred tax assets and liabilities reflect the tax rates expected
to be in effect for the years in which the differences are expected to reverse.
A valuation allowance is provided if it is more likely than not that some or the
entire deferred tax asset will not be realized.
Accounting for stock based compensation
Callisto has adopted Statement of Financial Accounting Standard No. 123,
"Accounting for Stock-Based Compensation" ("SFAS 123"). As provided for by SFAS
123, Callisto has also elected to continue to account for its stock-based
compensation programs according to the provisions of Accounting Principles Board
Opinion No. 25, "Accounting for Stock Issued to Employees ("APB 25")."
Accordingly, compensation expense has been recognized to the extent of employee
or director services rendered based on the intrinsic value of compensatory
options or shares granted under the plans. Callisto has also adopted the
disclosure provisions required by SFAS 123, as amended by SFAS 148, "Accounting
for Stock-Based Compensation - Transition and Disclosure, an amendment to FASB
Statement No. 123."
Had compensation cost for stock options granted been determined based upon the
fair value at the grant date for awards, consistent with the methodology
prescribed under SFAS 123, Callisto's net loss and net loss per share would have
been as follows:
Three Months Ended Nine Months Ended
September 30, September 30,
2003 2002 2003 2002
Net loss, as reported ($1,366,524) ($ 409,745) ($12,306,076) ($ 1,495,057)
=============================== =================================
Add: Stock-based compensation expense
recorded for compensatory stock options 468,437 81,027 3,774,987 248,981
Deduct: Total stock-based compensation
expense determined under fair value
based method for all awards (562,507) (82,918) (4,070,015) (254,653)
------------------------------ ---------------------------------
Pro forma net loss ($1,460,594) ($ 411,636) ($12,601,104) ($ 1,500,729)
=============================== =================================
Net loss per share:
Basic and diluted -as reported ( $0.06) ($ 0.02) ($ 0.60) ($ 0.09)
=============================== =================================
Basic and diluted -pro forma ($ 0.06) ($ 0.02) ($ 0.61) ($ 0.09)
=============================== =================================
The fair value of the options granted to employees during 2003 and 2002 ranged
from $1.26 to $5.53 on the date of the respective grant using the Black-Scholes
option-pricing model. The following weighted average assumptions were used for
2003 and 2002: no dividend yield, expected volatility of 0% to April 30, 2003
and 100% since Callisto's common stock began to trade publicly on June 16, 2003,
risk free interest rates of 2.87%-4.50% and an expected term of 7 to 10 years.
Cash and cash equivalents:
For purposes of the statements of cash flows, Callisto considers all highly
liquid investment instruments with an original maturity of three months or less
to be cash equivalents.
Research and development:
Callisto is engaged in various pharmaceutical patent and research and
development projects under arrangements with various research facilities and
universities whereby certain minimum annual fees and royalty payments are
required to be paid. Research and development costs are expensed as incurred and
include mainly expenditures made to research facilities and universities, as
well as legal and professional fees associated with filing and maintaining
Callisto's patent and license rights to its proposed products.
Loss per share:
The assumed exercise of all Callisto's outstanding options was excluded from the
computation of net loss per share due to their anti-dilutive effect as a result
of the net losses reported for the three and nine months ended September 30,
2003 and 2002.
3. Merger and consolidation:
On April 30, 2003 Webtronics, Inc. ("Webtronics") entered into a merger
agreement with Callisto Research Labs, LLC ("Callisto Research", formerly known
as Callisto Pharmaceuticals, Inc.) and Synergy, an unaffiliated company also in
the development stage, under which agreement Callisto Research and Synergy
agreed to merge in a stock for stock transaction and each become subsidiaries of
Webtronics. Webtronics subsequently changed its name to Callisto
Pharmaceuticals, Inc. Pursuant to the merger agreement 17,318,994 shares of
Webtronics common stock were issued to holders of Callisto Research common
stock; and 4,395,684 shares of Webtronics common stock were issued to holders of
Synergy common stock in exchange for outstanding Callisto Research and Synergy
common stock.
The 4,395,684 shares issued to the former shareholders of Synergy were valued at
$6,593,526. In addition net assumed liabilities in excess of Synergy assets
acquired at April 30, 2003 were as follows:
Cash $ 9,501
Accounts receivable 258,928
Rent deposit 44,746
Fixed assets 38,343
--------
Total assets acquired 351,518
Accounts payable and other liabilities assumed 591,446
--------
Net liabilities assumed in excess of assets acquired $239,928
========
The merged companies are considered to be in the development stage. No revenues
have been realized and all activities have been concentrated in research and
development of biopharmaceutical products yet to be approved by the Food and
Drug Administration. The value of the shares issued to former Synergy
shareholders in the merger plus the net liabilities assumed in excess of assets
acquired totaled $6,833,454. During the quarter ended September 30, 2003 certain
former Synergy shareholders returned 12,727 shares to Callisto under an
indemnification agreement, reducing purchased in-process research and
development expense by $19,091. This net amount was allocated in full to the
Synergy research and development projects which had not yet reached
technological possibility and having no alternative use was charged to purchased
in-process research and development expense.
The results of operations of Synergy for the period May 1, 2003 through
September 30, 2003 are included in the consolidated statement of operations for
the quarter and nine months ended September 30, 2003, as well as the
consolidated balance sheet as of September 30, 2003.
The following (unaudited) combined proforma results of operations for the nine
months ended September 30, 2003 and 2002 have been prepared as if the merger of
the companies had occurred at January 1, 2003, and 2002
2003 2002
---- ----
Revenues $ - $ -
Net loss (12,754,343) (2,384,062)
Net loss per common share
(23,204,851 common shares) ($0.55) ($0.10)
4. Stock option plan:
In 1996, Callisto adopted an incentive and non-qualified stock option plan
(the"Plan") for employees, consultants and outside directors to purchase up to
2,000,000 shares of common stock. The Plan was amended in December 2002 to
increase the number of shares authorized under the Plan to 10,000,000. The
option term for options granted under the Plan is ten years from date of grant.
Additionally Callisto has granted stock options not subject to the Plan.
The following represent options outstanding for the nine months ended September
30, 2003 and for the years ended December 31, 2002 and 2001:
Total
-----
Balance, January 1, 2001 1,931,505
Year 2001:
Granted 400,000
Exercised -
----------
Balance, December 31, 2001 2,331,505
Year 2002:
Granted 330,000
Cancelled
Exercised -
----------
Balance, December 31, 2002 2,661,505
Nine month ended September 30, 2003:
Granted 3,731,055
Exercised -
Cancelled (1,717,333)
----------
Balance, September 30, 2003 4,675,227
==========
Included in the above balance at September 30, 2003 were 2,446,338 non-Plan
options.
Options are exercisable at various prices as follows at September 30, 2003:
Exercise
Price Total
----- -----
$0.75 615,839
1.10 500,000
1.25 400,000
1.30 383,055
1.50 1,968,000
1.75 27,500
1.95 266,667
2.25 90,000
2.85 262,500
4.90 125,000
6.75 36,666
---------
4,675,227
=========
5. Income taxes:
At December 31, 2002, Callisto had available net operating tax loss carry
forwards of approximately $8,000,000 for income tax purposes expiring through
2022 to offset future taxable income. The net deferred tax asset has been fully
offset by a valuation allowance due to uncertainties regarding realization of
benefits from these future tax deductions. As a result of the change in control
provisions of Internal Revenue Code Section 382, a significant portion of these
net operating loss carryforwards may be subject to limitation on future
utilization.
6. Contractual obligations:
On August 28, 2002, Callisto's wholly-owned subsidiary, Synergy Pharmaceuticals
Inc. entered into a license agreement with AnorMED Inc. to license Atiprimod
from AnorMED. The license agreement provides for milestone payments and
royalties on net sales. Commencing on January 1, 2004 and on January 1 of each
subsequent year Synergy is obligated to pay AnorMED a maintenance fee of
$200,000.
On June 13, 2003, Callisto entered into employment agreements with Gary S.
Jacob, Ph.D., Chief Executive Officer and Chief Scientific Officer and Kunwar
Shailubhai, Ph.D., Executive Vice President and Head of Research and
Development. Each of their employment agreements is for a term of 18 months
beginning June 13, 2003 and is automatically renewable for successive one year
periods at the end of the term. Dr. Jacob's salary is $225,000 per year and he
is eligible to receive a cash bonus of up to 15% of his salary per year. Dr.
Jacob received a grant of 500,000 stock options which vest over a three year
period and are exercisable at $1.50 per share. Dr. Shailubhai's salary is
$170,000 per year and he is eligible to receive a cash bonus of up to 15% of his
salary per year. Dr. Shailubhai received a grant of 25,000 stock options which
are fully vested and have an exercise price of $1.50 per share. Dr. Shailubhai
also received a grant of 325,000 stock options which vest over a three year
period and are exercisable at $1.50 per share.
On September 23, 2003, Callisto entered into an employment agreement with Donald
H. Picker, Ph.D., our Vice President, Drug Development. The employment agreement
is for a term of 18 months beginning September 23, 2003 and is automatically
renewable for successive one year periods at the end of the term. Dr. Picker's
salary is $175,000 per year and he is eligible to receive a cash bonus of up to
$45,000 per year upon the achievement of certain performance milestones. Dr.
Picker received a grant of 325,000 stock options which vest over a three year
period and are exercisable at $1.50 per share.
On August 20, 2003 Callisto entered into a five year lease for its corporate
headquarters in New York City comprising 2,722 square feet with an approximate
fixed rent of $100,000 annually through 2008.
7. Subsequent Events:
In November 2003, Callisto closed on a sufficient amount of funds in a private
placement of common stock such that it no longer had a working capital
deficiency.
Item 2. Management's Discussion and Analysis of Financial Condition and
Results of Operations
The following discussion should be read in conjunction with our condensed
consolidated financial statements and notes to those statements. In addition to
historical information, the following discussion and other parts of this
quarterly report contain forward-looking information that involves that involves
risks and uncertainties.
Overview
We are a development stage biopharmaceutical company, whose primary focus is on
biopharmaceutical product development. Since inception in September 1996 our
efforts have been principally devoted to research and development, securing
patent protection, obtaining corporate relationships and raising capital. Since
inception through September 30, 2003, we have sustained cumulative net losses of
$21,396,619. Our losses have resulted primarily from expenditures incurred in
connection with the purchase of in-process research and development, stock
compensation expense, patent filing and maintenance, outside accounting and
legal services and regulatory consulting fees.
From inception through September 30, 2003 we have not generated any revenue from
operations. We expect to incur additional losses to perform further research and
development activities. We do not currently have any commercial
biopharmaceutical products, and do not expect to have such for several years, if
at all. Our lead drug candidate, Atiprimod, is a small molecule, orally
available drug, with antiprolifererative and antiangiogenic activity. Atiprimod
successfully completed Phase I/IIa clinical trials in rheumatoid arthritis
patients and we plan to enter Atiprimod in a safety and proof of principle
clinical trial in multiple myeloma patients. The IND application
(Investigational New Drug) for Phase I/IIa of these clinical trials was filed
with the FDA on September 23, 2003.
Our product development efforts are thus in their early stages and we cannot
make estimates of the costs or the time it will take to complete. The risk of
completion of any program is high because of the long duration of clinical
testing, extended regulatory approval and review cycles and uncertainty of the
costs. Net cash inflows from any products developed may take several years to
achieve. We could however receive grants, contracts or technology licenses in
the short-term. The amount and timing of these inflows, if any, is not known. We
are also in the process of raising additional capital through a private
placement of common stock which began in July 2003. There can be no assurance we
will be successful in these fund raising efforts. In November 2003, we closed on
a sufficient number of funds in a private placement of common stock such that we
no longer have a working capital deficiency.
The accompanying unaudited condensed consolidated financial statements have been
prepared assuming that we will continue as a going concern. We believe that
current resources will be sufficient to support planned operations through the
fourth quarter 2003. These circumstances raise substantial doubt about our
ability to continue as a going concern. Our plan is to continue product
development beyond December 31, 2003 and seek additional research support and
investment capital. There is no assurance that we will be successful in
obtaining sufficient financing on terms acceptable to us. In the event that we
are unable to raise additional funds, planned operations will need to be scaled
back or discontinued. The financial statements do not include any adjustments
that might result from the outcome of this uncertainty.
On April 30, 2003, pursuant to an Agreement and Plan of Merger dated March 10,
2003, as amended April 4, 2003, Synergy Acquisition Corp., our wholly-owned
subsidiary, merged into Synergy Pharmaceuticals Inc. and Callisto Acquisition
Corp., our wholly-owned subsidiary, merged into the predecessor of Callisto
Research Labs, LLC. As a result of the merger Callisto Research and Synergy are
our wholly owned subsidiaries. We issued 17,318,994 shares of our common stock
in exchange for all outstanding Callisto Research, LLC common stock and an
additional 4,395,684 shares in exchange for outstanding Synergy common stock.
During the quarter ended September 30, 2003 certain former Synergy shareholders
returned 12,727 shares to Callisto under an indemnification agreement.
Significant Accounting Policies
Financial Reporting Release No. 60, requires all companies to include a
discussion of critical accounting policies or methods used in the preparation of
financial statements. Note 2 of the notes to our condensed consolidated
financial statements includes a summary of all significant accounting policies
and methods used in the preparation of our financial statements, the most
critical of which are:
Accounting for stock based compensation
Callisto has adopted Statement of Financial Accounting Standard No. 123,
"Accounting for Stock-Based Compensation" ("SFAS 123"). As provided for by SFAS
123, Callisto has also elected to continue to account for its stock-based
compensation programs according to the provisions of Accounting Principles Board
Opinion No. 25, "Accounting for Stock Issued to Employees ("APB 25")."
Accordingly, compensation expense has been recognized to the extent of employee
or director services rendered based on the intrinsic value of compensatory
options or shares granted under the Plan. Callisto has also adopted the
disclosure provisions required by SFAS 123, as amended by SFAS 148, "Accounting
for Stock-Based Compensation - Transition and Disclosure, an amendment to FASB
Statement No. 123."
Research and development:
Callisto is engaged in various pharmaceutical patent and research and
development projects under arrangements with various research facilities and
universities whereby certain minimum annual fees and royalty payments are
required to be paid. Research and development costs are expensed as incurred and
include mainly expenditures made to research facilities and universities, as
well as legal and professional fees associated with filing and maintaining
Callisto's patent and license rights to its proposed products.
Results of Operations
Three Months Ended September 30, 2003 and September 30, 2002
We had no revenues during the three months ended September 30, 2003 and
September 30, 2002 because we do not have any commercial biopharmaceutical
products, and we do not expect to have such products for several years, if at
all.
Research and development expenses increased approximately $434,549 or 307% to
$576,266 for the three months ended September 30, 2003 from $141,717 for the
same period in 2002. The results of operations of Synergy for the period July 1,
2003 through September 30, 2003 are included in the consolidated statement of
operations for the quarter ended September 30, 2003, as well as the consolidated
balance sheet as of September 30, 2003, and are not included in the results of
the same periods of 2002. Of this increase in research and development expense,
$347,619 was attributable to costs associated with preparing and filing our IND
application for Atiprimod. These IND related costs included quantitative
analysis and synthesis, as well as pre-clinical management consulting fees paid
to contract research organizations to develop and advise on IND requirements,
proposed clinical trial protocols, site selection and principal investigator
contracting. Our IND was filed on September 23, 2003. Also contributing to this
increase in research and development expense were higher patent costs and
payroll as we retained three Synergy executive staff scientists subsequent to
the Synergy merger. Annual compensation and other benefits associated with the
employment of Drs. Jacob, Picker and Shailubhai is discussed in detail elsewhere
in this quarterly report.
General and administrative expenses for the three months ended September 30,
2003 increased $153,911 or 82% to $340,912, from $187,001 for the three months
ended September 30, 2002. The increase was primarily due to higher legal,
accounting and professional fees related to regulatory filing and fund raising
efforts. In addition facilities and related office overhead increased as we
opened our New York City headquarters during the quarter ended September 30,
2003.
Net loss for the three months ended September 30, 2003 was $1,366,524 compared
to a net loss of $409,745 incurred for the three months ended September 30,
2002. The increase in the net loss is the result of higher research,
development, general and administrative expenses discussed above, plus $468,437
of stock based compensation expense during the three months ended September 30,
2003, as compared to $81,027 of stock based compensation expense recorded during
the three months ended September 30, 2002.
Nine Months ended September 30, 2003 and September 30, 2002.
We had no revenues during the nine months ended September 30, 2003 and September
30, 2002 because we do not have any commercial biopharmaceutical products, and
we do not expect to have such products for several years, if at all.
Research and development expenses increased $445,008 or 101% to $885,252 for the
nine months ended September 30, 2003 from $440,244 for the same period in 2002.
The increase in research and development expense was primarily attributable to
higher costs associated with preparing and filing our IND application for
Atiprimod, discussed above in the quarter ended September 30, 2003, plus higher
patent costs and higher payroll as we retained three Synergy executive staff
scientists subsequent to the Synergy merger.
General and administrative expenses for the nine months ended September 30, 2003
of $831,474 were approximately the same as $805,832 for the nine months ended
September 30, 2002. These expenses primarily comprise legal, accounting and
professional fees related to the Synergy merger and our regulatory filing,
insurance and fund raising efforts. During the quarter ended June 30, 2002 we
incurred a charge of $400,000 associated with the purchase of Webtronics, Inc.,
a non-operating public company. In addition facilities and related office
overhead increased slightly as we opened our New York City headquarters during
the quarter ended September 30, 2003.
Net loss for the nine months ended September 30, 2003 was $12,306,076 compared
to a net loss of $1,495,057 incurred for the nine months ended September 30,
2002. The increase in our net loss is the result of higher research and
development expenses and general and administrative expenses discussed above,
plus $3,774,987 of stock based compensation expense recorded during the nine
months ended September 30, 2003, as compared to $248,981 recorded during the
nine months ended September 30, 2002. The remaining balance of unamortized
deferred stock based compensation expense, presented in the shareholder's equity
section of our September 30, 2003 balance sheet, totaled $6,239,033 .
During the nine months ended September 30, 2003 we also incurred $6,814,363 of
net purchased in-process research and development expense related to the Synergy
merger. There was no such expense during the same period ended September 30,
2002.
Liquidity and Capital Resources
As of September 30, 2003 we had $703,903 in cash and cash equivalents, compared
to $2,223,462 as of December 31, 2002. This decrease in cash of $1,519,559
during the nine months ended September 30, 2003 was principally the result of
cash used in operating activities. Our working capital as of September 30, 2003
was deficient by $234,565.
Our working capital requirements will depend upon numerous factors including but
not limited to the nature, cost and timing of: pharmaceutical research and
development programs; pre-clinical and clinical testing; obtaining regulatory
approvals; technological advances and our ability to establish collaborative
arrangements with research organizations and individuals needed to commercialize
our products.
Our capital resources will be focused primarily on the clinical development and
regulatory approval of Atiprimod for multiple myeloma and bone resorption
disease, a major complication associated with multiple myeloma disease. We plan
to enter Atiprimod in a safety and proof of principle clinical trial in multiple
myeloma patients. The IND application for Phase I/IIa of these trials was filed
with the FDA on September 23, 2003.
Our product development efforts are thus in their early stages and we cannot
make estimates of the costs or the time it will take to complete. The risk of
completion of any program is high because of the long duration of clinical
testing, extended regulatory approval and review cycles and uncertainty of the
costs. Net cash inflows from any products developed make take several years to
achieve. We could however receive grants, contracts or technology licenses in
the short-term. The amount and timing of these inflows, if any, is not known.
We are also in the process of raising additional capital through a private
placement of common stock which began in July 2003. There can be no assurance we
will be successful in these fund raising efforts. In November 2003, we closed on
a sufficient amount of funds in a private placement of common stock such that we
no longer have a working capital deficiency.
Contractual Obligations
On August 28, 2002, our wholly-owned subsidiary, Synergy Pharmaceuticals Inc.
entered into a license agreement with AnorMED Inc. to license Atiprimod from
AnorMED. The license agreement provides for milestone payments and royalties on
net sales. Commencing on January 1, 2004 and on January 1 of each subsequent
year Synergy is obligated to pay AnorMED a maintenance fee of $200,000.
On September 23, 2003, we entered into an employment agreement with Donald H.
Picker, Ph.D., our Vice President, Drug Development. The employment agreement is
for a term of 18 months beginning September 23, 2003 and is automatically
renewable for successive one year periods at the end of the term. Dr. Picker's
salary is $175,000 per year and he is eligible to receive a cash bonus of up to
$45,000 per year upon the achievement of certain performance milestones. Dr.
Picker received a grant of 325,000 stock options which vest over a three year
period and are exercisable at $1.50 per share.
On August 20, 2003 we entered into a five year lease for our corporate
headquarters in New York City comprising 2,722 square feet with an approximate
fixed rent of $100,000 annually through 2008.
ITEM 3. Controls and Procedures
Our Chief Executive Officer and Principal Financial Officer, based on the
evaluation of our disclosure controls and procedures (as defined in Rules
13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended)
required by paragraph (b) of Rule 13a-15 or Rule 15d-15, as of the end of the
period covered by this report, have concluded that our disclosure controls and
procedures were effective to ensure the timely collection, evaluation and
disclosure of information relating to our company that would potentially be
subject to disclosure under the Securities Exchange Act of 1934, as amended, and
the rules and regulations promulgated there under.
During the three months ended September 30, 2003, there were no changes in our
internal control over financial reporting identified in connection with the
evaluation required by paragraph (d) of Rule 13a-15 or Rule 15d-15 that has
materially affected, or is reasonably likely to materially affect, our internal
control over financial reporting.
PART II. OTHER INFORMATION
Item 6. Exhibits and Reports on Form 8-K
(a) Exhibits
10.3 Employment Agreement dated September 23, 2003 by and between
Callisto Pharmaceuticals, Inc. and Donald Picker.
10.4 License Agreement dated as of August 28, 2002 between AnorMED
Inc. and Synergy Pharmaceuticals Inc.*
31.1 Certification of Chief Executive Officer required by Rule
13a-14(a)/15d-14(a) under the Exchange Act.
31.2 Certification of Principal Financial Officer required by Rule
13a-14(a)/15d-14(a) under the Exchange Act.
32.1 Certification of Chief Executive Officer pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.
32.2 Certification of Principal Financial Officer pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.
-------------
*Confidential treatment requested
(b) Reports on Form 8-K.
On July 1, 2003, we filed a Form 8-K announcing the appointment of new
members to Callisto's Board of Directors and certain management changes in
connection with the merger agreement with Synergy Pharmaceuticals Inc.
On August 6, 2003, we filed a Form 8-K disclosing that Baum & Company,
PA had resigned as the independent accountants for Callisto Pharmaceuticals,
Inc. and BDO Seidman LLP had been hired as the new independent accountants.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
CALLISTO PHARMACEUTICALS, INC.
------------------------------
(Registrant)
Date: November 14, 2003 By: /s/ Gary S. Jacob
----------------------------
Gary S. Jacob
Acting Chief Executive Officer
Date: November 14, 2003 By: /s/ Bernard Denoyer
-----------------------------
Bernard Denoyer
Principal Financial Officer